Study of Monoclonal Antibody in Breast Cancer
Author Information
Author(s): H.P. Kalofonos, J.M. Sackier, M. Hatzistylianou, S. Pervez, J. Taylor-Papadimitriou, J.H. Waxman, J.P. Lavender, C. Wood, A.A. Epenetos
Primary Institution: Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
Hypothesis
Can HMFG1 F(ab')2 fragments localize breast cancer lesions more effectively than intact IgG?
Conclusion
HMFG1 F(ab')2 fragments can localize breast cancer lesions specifically and faster than intact IgG, but the overall sensitivity is relatively low.
Supporting Evidence
- Mean tumor uptake of HMFG1 F(ab')2 fragments was significantly higher than intact IgG at 24 hours.
- Lymph node metastases showed higher antibody uptake than corresponding primary tumors.
- Successful localization was observed in approximately 50% of primary and metastatic lesions.
Takeaway
This study looked at a special type of medicine that helps find breast cancer. It showed that a smaller part of the medicine works better and faster than the whole thing.
Methodology
Patients received indium-111 labelled HMFG1 F(ab')2 fragments or intact IgG, followed by tumor resection or external body scintigraphy to evaluate antibody uptake.
Limitations
The method has relatively low sensitivity and may not detect all tumor sites.
Participant Demographics
Patients aged 38 to 74 years, with a mean age of 56.5 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website